155 related articles for article (PubMed ID: 26186486)
1. Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients.
Li Y; Shi Y; Liao Y; Yan L; Zhang Q; Wang L
Int Immunopharmacol; 2015 Sep; 28(1):435-43. PubMed ID: 26186486
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM
Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
4. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
5. Th1, Th2, Th17 cell subsets in two different immunosuppressive protocols in renal allograft recipients (Sirolimus vs mycophenolate mofetil): A cohort study.
Eteghadi A; Pak F; Ahmadpoor P; Jamali S; Karimi M; Yekaninejad MS; Kokhaei P; Nafar M; Amirzargar AA
Int Immunopharmacol; 2019 Feb; 67():319-325. PubMed ID: 30576916
[TBL] [Abstract][Full Text] [Related]
6. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
Kim KW; Chung BH; Kim BM; Cho ML; Yang CW
Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
[TBL] [Abstract][Full Text] [Related]
7. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
Li Y; Shi Y; Huang Z; Bai Y; Niu Q; Cai B; Wang L; Feng W
Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083
[TBL] [Abstract][Full Text] [Related]
8. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
Niemczyk M; Zegarska J; Pawłowska M; Wyzgał J; Ciszek M; Paczek L
Transpl Immunol; 2009 Jan; 20(3):139-42. PubMed ID: 18834941
[TBL] [Abstract][Full Text] [Related]
9. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
10. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
Libetta C; Sepe V; Zucchi M; Portalupi V; Meloni F; Rampino T; Dal Canton A
Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
[TBL] [Abstract][Full Text] [Related]
11. The imbalance between Tregs, Th17 cells and inflammatory cytokines among renal transplant recipients.
Ma L; Zhang H; Hu K; Lv G; Fu Y; Ayana DA; Zhao P; Jiang Y
BMC Immunol; 2015 Sep; 16():56. PubMed ID: 26400627
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
Chu ZQ; Ji Q
Transplant Proc; 2013; 45(1):153-6. PubMed ID: 23375290
[TBL] [Abstract][Full Text] [Related]
13. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
15. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
[TBL] [Abstract][Full Text] [Related]
16. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
18. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation.
Egbuna OI; Davis RB; Chudinski R; Pavlakis M; Rogers C; Molakatalla P; Johnson SR; Karp S; Monaco AP; Tang H; Hanto DW; Mandelbrot DA
Transplantation; 2009 Sep; 88(5):684-92. PubMed ID: 19741466
[TBL] [Abstract][Full Text] [Related]
20. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
Levitsky J; Mathew JM; Abecassis M; Tambur A; Leventhal J; Chandrasekaran D; Herrera N; Al-Saden P; Gallon L; Abdul-Nabi A; Yang GY; Kurian SM; Salomon DR; Miller J
Hepatology; 2013 Jan; 57(1):239-48. PubMed ID: 22234876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]